#cannabisaficionado

Cannabis

Moicano–Nolan Sets Up a Halloween Fight Night in Las Vegas

The lightweight main event leads a full Halloween card, with an important distinction for cannabis-minded visitors: legal retail does not mean consumption at a sporting event.

Published

on

Empty boxing ring in a bright gym with tall windows
Advertisement Back2Grow Advertisement

Renato Moicano and Tom Nolan headline UFC Fight Night at Meta APEX in Las Vegas on Saturday, October 31. UFC’s current event page lists prelims at 2 p.m. and the main card at 5 p.m. for Phoenix viewers, giving Halloween an afternoon-to-evening sports option before the night’s other plans.

For cannabis-minded fans considering a Las Vegas visit, the useful connection is the setting and its rules. Nevada permits regulated adult-use cannabis, but that does not make a fight ticket permission to consume at the event. The distinction matters when a weekend combines a sporting venue, a hotel and an interest in the city’s cannabis scene.

A lightweight main event with two different positions

The current card places Moicano at No. 12 and Nolan at No. 14 in the lightweight matchup. Those are the rankings displayed on the event listing when checked, rather than numbers carried forward from an earlier announcement. The promotion’s September ticket release had a different ranking for Moicano, illustrating why the live card is the better starting point.

UFC’s September announcement explains how the matchup took shape: an injury to Brian Ortega removed his planned bout with Moicano from UFC 331, after which Moicano was assigned Nolan for October 31. That is the scheduling history, not a suggestion that Ortega is part of Saturday’s card.

For a viewer, the main event supplies a straightforward point of entry: two ranked lightweights meeting at the top of a Fight Night program. It is possible to follow that contest without treating the rest of the evening as background. Earlier bouts introduce different divisions and can change the pace of a viewing session well before the headliners enter.

What the current main card includes

UFC lists Randy Brown against Jacobe Smith at welterweight, Ode’ Osbourne against Cody Durden at flyweight, and Yana Santos against Luana Santos at women’s bantamweight. The Santos matchup is displayed as No. 6 against No. 7. Jean-Paul Lebosnoyani against Farman Hasanov is also listed at welterweight.

Those pairings make this more than a single-fight appointment. Fans interested in the smaller weight classes can note the flyweight bout, while the two welterweight matchups offer another thread to follow. This is a guide to the advertised card, not a prediction of winners or a report that the fights have already happened.

Cards can change. Use the official event page again on Saturday if a particular matchup is the reason for watching or traveling. Promotional announcements are useful records of what was planned; they should not override a later organizer update.

There is a full preliminary program

The current prelims include Francis Marshall against Dakota Hope at featherweight, Rodrigo Sezinando against Theodor Berggren at welterweight, and Julian Erosa against Jeongyeong Lee at featherweight. At middleweight, Zachary Reese is listed against Mickey Gall and Nick Klein against Joe Kropschot.

The women’s preliminary bouts listed are Talita Alencar against Piera Rodriguez at strawweight and Lucia Szabová against Tainara Lisboa at flyweight. Someone watching from the opening broadcast will therefore see several divisions before the main-card start. Someone joining later should use the scheduled main-card window rather than assume it is the headliners’ exact walkout time.

How to watch from Phoenix

UFC’s official broadcast announcement lists Paramount+ for the entire U.S. card: prelims at 5 p.m. Eastern and the main card at 8 p.m. Eastern. On October 31, that corresponds to 2 and 5 p.m. in Phoenix and Las Vegas.

Check the service’s current access requirements and local availability before settling on a viewing location. The preliminary and main-card times describe broadcast blocks, not guaranteed start times for individual bouts. Leave room for the program to unfold rather than organizing a watch party around an assumed minute for the main event.

For attendance rather than streaming, UFC’s event page links to its authorized ticket seller; check current availability there.

Keep the cannabis plan separate from venue access

The Nevada Cannabis Compliance Board says adult-use buyers must be at least 21 and purchase from a state-licensed retailer. It prohibits public consumption and consumption in a moving vehicle, including by passengers. Licensed consumption lounges are a distinct permitted setting; a sports venue is not automatically one.

The board also says private-property consumption depends on the owner allowing it and warns against impaired driving. Plan transportation before any consumption and confirm property rules rather than assume a hotel booking settles them. None of this implies cannabis use by Moicano, Nolan or any other athlete. It gives fans a practical way to enjoy the fight weekend while keeping the event, the accommodation and cannabis permissions clear.

Illustrative stock boxing gym; not the UFC Octagon, Meta APEX or the October 31 event. Photo: Ron Lach / Pexels.

Health

Utah Opens Comments on Medical Cannabis Rule Repeals as Oversight Moves

Utah is proposing to repeal six DHHS cannabis rules as oversight moves to Agriculture and Food. Comments are open through December 15.

Published

on

Close-up of a person using a blue pen to write on a clipboard.

Utah has opened a comment period on proposed repeals of six Department of Health and Human Services medical cannabis rules as oversight moves to the Department of Agriculture and Food. Comments are due December 15, 2026. The word “repeal” can sound alarming when your access to medicine depends on a state program, so we went to the transition documents before treating it as a change in patient eligibility.

The official notice describes an agency transfer implementing House Bill 389, not a proposal to close Utah’s medical cannabis program. It says the rules will be readopted by the Utah Department of Agriculture and Food, or UDAF, in early 2027. Proposed successor rules appear in the same November 15 issue of the Utah State Bulletin.

Which rules are being moved?

The six DHHS rules cover definitions; electronic verification and inventory-system registration, limits and confidentiality; dosing and partial filling; pharmacy medical provider education; expedited compassionate-use review; and Compassionate Use Board hearing procedures. These are parts of the machinery that makes a medical program function, even when patients rarely need to read the rule numbers.

The notice directs people to pages 248–267 of the bulletin for the repeal documents. Written comments on these DHHS proposals can be sent to dlbcrules@utah.gov through December 15. Identify the relevant rule and the concern clearly so the agency can connect a comment to the actual proposal.

We would focus comments on the practical handoff: how to find the right contact, how a pending matter will be handled and where updated instructions will appear. A specific question about a registration or review process is easier to address than a broad objection to a rule number disappearing.

Why is Utah changing agencies?

The state’s 2026 medical cannabis law summary says DHHS duties transition to UDAF by January 1, 2027. It states that the change will not affect patient access and that patients, providers and industry will be informed when the transition is complete. Once transferred, UDAF is to oversee all aspects of the program.

That is the state’s stated plan, rather than independent evidence that every administrative step has already happened. The distinction matters now: a statutory transfer date, a proposed rule’s possible effective date and a promised notification describe different milestones. We would look for the relevant final notice before assuming a particular process has changed.

Other provisions in the law summary address patient identification, caregivers and purchasing. Those separate changes should not be attributed automatically to these six repeal filings. Our previous coverage of Utah’s proposed patient voucher rules concerns another part of the year’s implementation work, with its own requirements and questions.

What does the original filing say?

The November 15 Utah State Bulletin explains that DHHS intends the repeals to take effect at the same time as, or shortly after, UDAF adopts replacement provisions under Title R67. Its analyses anticipate continuity and no new compliance costs from the repeals themselves, while directing broader legislative fiscal effects to HB 389’s fiscal note.

The filings list December 22 as a possible effective date and explicitly warn that this is not an established effective date. We would not put “new rules start December 22” in a calendar on that basis. The accompanying explanation anticipates the UDAF medical cannabis rules taking effect in early 2027, making final coordination worth watching.

That paperwork also shows why an isolated repeal headline can mislead. Removing an old agency’s rule and establishing the receiving agency’s authority can be paired actions. To understand the practical result, compare the outgoing provision with its successor rather than assume the subject is no longer regulated.

The state’s provider guidance gives this transfer a practical context. Its electronic verification system holds cards, recommendations and purchase information. A recommending medical provider handles certification, while a pharmacy medical provider consults on products and amounts. Those separate roles help explain why registration, confidentiality and dosing procedures need clear continuity when the responsible agency changes.

What should patients watch next?

Keep the December 15 comment deadline separate from your own card or appointment dates. The proposal is not an instruction to stop using the program, skip a renewal or change treatment. Questions about a personal registration or a pending petition belong with the program’s official contacts and your treating provider where appropriate.

Our priority is continuity you can actually navigate: clear instructions, a working route for questions and final notices that match the promised handoff. Utah has described the direction of travel. The next meaningful test is whether the completed transition leaves patients able to find and use the processes they need without confusion about which agency is responsible.

Illustrative stock photograph of paperwork review; not a Utah patient, official or agency proceeding. Photo: Kindel Media / Pexels.

Continue Reading

Cannabis

USPS Says Medical Cannabis Remains Nonmailable While It Reviews Policy

A November 18 statement reported by Marijuana Moment leaves patients with a clear distinction between state delivery plans and the Postal Service’s current position.

Published

on

Hands sealing a cardboard parcel with clear packing tape.

The U.S. Postal Service says medical marijuana remains nonmailable while it reviews the effects of federal rescheduling. That position, reported November 18 by Marijuana Moment, follows the announcement of a Georgia medical-cannabis shipping program. For patients, the immediate issue is the gap between a new delivery service’s plans and the postal agency’s stated rules.

A state’s permission to arrange medical cannabis delivery does not itself establish that USPS will accept the package. The current dispute concerns the carrier and federal mailability requirements, alongside state patient eligibility. It should not be read as a nationwide invitation for patients to send cannabis to one another.

What the Postal Service told reporters

Tom Angell’s reporting for Marijuana Moment attributes the statement to USPS senior public relations representative Felicia Lott. She said the agency and the Postal Inspection Service are reviewing medical marijuana’s mailability after its reclassification. She also said a future change would place it within the rules for prescription drugs containing controlled substances.

The outlet reported that USPS did not immediately provide a timetable for reaching a decision or explain where a decision would be announced. Georgia regulator Andrew Turnage disputed the agency’s interpretation in comments to the same outlet. Those are attributed positions in an unresolved policy disagreement, rather than evidence that the review has already produced a new rule.

That absence of a published decision matters. “Under review” describes work in progress. It does not tell a patient that a carrier has approved an individual shipment, and it does not establish that a state operator’s proposed method has been accepted by the Postal Service.

Why the Georgia announcement drew attention

In a November 17 company release, Botanical Sciences and Edibles.com announced a Georgia shipping platform for registered medical patients. The companies described a separate registry-verified ordering system with identity checks and delivery safeguards. They said the initial service would reach selected Botanical Sciences patients before expanding.

The release connects the launch to Georgia’s September 30 adoption of a medical-cannabis delivery rule. Its language describes what the companies intend to offer under the state framework. It is not a Postal Service authorization, and its claimed national first has not been independently established here.

The distinction is useful even outside Georgia. A delivery announcement can explain who may order, which products are offered and how the business plans to verify recipients. Whether a chosen carrier may transport those products is a further question. A tracking number or signature requirement records delivery activity; it does not independently establish that the contents are mailable.

What the published postal framework requires

USPS Publication 52, section 453, places responsibility on mailers to comply with postal regulations and applicable federal, state and local laws. It says mailing a controlled substance is unlawful when its distribution is unlawful. Controlled substances do not become ordinary parcels simply because the mailing stays within one state.

The section lists limited conditions for domestic mailing, including qualifying DEA-registered or exempt parties, approved mail-back programs and authorized dispensers sending mailable prescription medicines. These are defined channels with conditions, not a general exception for anyone holding a medical cannabis card.

The framework also treats hemp-based products separately, subject to legal compliance. That distinction makes product classification important: a seller’s use of “hemp,” “medical” or “CBD” in marketing cannot replace the applicable legal test. Patients should not infer that one kind of cannabinoid shipment proves every other kind is permitted.

What patients should ask before relying on shipping

A useful starting point is to ask the licensed provider which delivery method it currently offers and what authority supports that method. Ask whether the service is operating now, whether the patient’s address is eligible and how identity will be checked. Those details are especially important when public statements from the provider and the carrier do not align.

Patients should also distinguish commercial delivery by an authorized provider from personally mailing products to a friend, relative or another patient. The Georgia announcement does not establish permission for personal redistribution. Nor does the Postal Service’s review promise that a future change will cover every medical product, sender or recipient.

For now, the meaningful next development would be an official postal decision or updated published guidance, followed by a clear explanation from the state regulator and the service provider. A company announcement and an agency review are separate milestones. Until those positions are reconciled, patients should confirm the current delivery arrangements with their licensed provider rather than treat an announced shipping model as settled postal policy.

A review can change future policy, but it cannot supply an effective date that has not been announced.

Illustrative parcel stock photograph; not USPS mail, a cannabis shipment or the Georgia service. Photo: Liza Summer / Pexels.

Continue Reading

Cannabis

Philadelphia Urges Pennsylvania to Put Adult-Use Cannabis on Its Legislative Agenda

Council’s call for state legislation adds pressure after the election, while patient access and any future adult-use market remain separate questions.

Published

on

A person placing a white envelope marked Vote into a ballot box.

Philadelphia City Council is pressing Pennsylvania lawmakers to put adult-use cannabis legalization on their agenda after the November election. The resolution calls for a regulated market with public-health protections and community reinvestment. It does not create recreational sales in Philadelphia or change who can enter Pennsylvania’s existing medical program.

Tom Angell reported for Marijuana Moment that council adopted the measure by voice vote November 19. The city’s official file for Resolution 260998 contains its text and sponsors, but the online action history and meeting minutes were not finalized when checked. The adoption date is therefore attributed to that reporting rather than presented as an independently verified roll-call result.

A city request aimed at state lawmakers

Councilmember Jim Harrity sponsored the resolution with Council President Kenyatta Johnson and eight other councilmembers. Its argument centers on the newly elected Democratic majorities in Pennsylvania’s House and Senate and the opportunity to revisit a policy that has repeatedly stalled.

The text asks the General Assembly to enact adult-use legislation and develop rules addressing safety and the distribution of economic benefits. It identifies testing, labeling, packaging, age checks and restrictions on advertising and retail locations as parts of a responsible framework. These are priorities the council wants lawmakers to address, not a finished statewide licensing system.

That distinction leaves important policy choices unresolved. A statement supporting regulation does not tell an applicant how licenses would be awarded, tell a municipality where stores could open or tell a shopper when sales would begin. Those details would depend on legislation and implementation rather than the council resolution alone.

Political opportunity does not settle the timetable

Angell’s reporting also highlights a limit to expectations after the election. Presumptive Senate President Pro Tempore Jay Costa has said legalization is not among the immediate highest priorities and would be discussed over the coming months. That makes the council’s intervention a push for attention, rather than evidence that a statewide bill is about to pass.

The report describes previous disagreements over how Pennsylvania should organize legal sales, including a House-backed state-store approach and competing Senate proposals. The existence of earlier bills does not identify which model a new majority will ultimately choose. Nor should an earlier proposal’s possession limits or tax rates be presented as rules already adopted for consumers.

For readers following the debate, the consequential milestones are a specific bill, its committee and floor actions, and an enacted implementation schedule. A favorable election result may change the political setting, but it cannot substitute for those decisions.

The medical program remains a separate route

Pennsylvania’s Department of Health patient guidance describes access through residency, an eligible serious medical condition, certification by an approved practitioner and the program’s identification process. Patients obtain medical cannabis through Pennsylvania dispensaries using the required identification. A council endorsement of adult-use legislation does not waive those conditions.

The department also describes caregivers as designated people who can obtain products for a patient. Caregivers register for identification and undergo a background check. That structure matters for households where the person receiving care cannot independently make a dispensary visit; it is more specific than treating every adult resident as an eligible shopper.

The patient guidance separates registration from practitioner certification and the identification-card payment process. Someone reading legalization headlines should not assume those steps have ended. Questions about an individual’s eligibility or certification remain matters for the program and an approved practitioner, not an inference from political statements.

Existing medical taxes are not proposed adult-use taxes

The Department of Revenue’s medical-marijuana guidance provides another useful distinction. Growers and processors pay a 5 percent tax on gross receipts from medical-marijuana sales to dispensaries. The department says medical marijuana itself is not subject to sales tax, although accessories can be.

Those are features of the existing medical system. A forecast about adult-use revenue, or a tax rate appearing in a legalization proposal, belongs to a different policy discussion. It should not be added to a medical patient’s purchase as though council had changed the tax code.

Revenue also distinguishes the roles of the departments: Health handles permits connected with production and sale, while Revenue administers the relevant taxes and participates in tax-clearance review. Legalization would require lawmakers to decide how any expanded market fits those existing responsibilities.

For now, the immediate change is renewed political pressure from Philadelphia. The practical rules for patients remain in place, while the proposed adult-use market still depends on state action. That is the useful way to read this week’s resolution: a call to legislate, with consumer access and business permissions still awaiting the legislation itself.

Illustrative voting stock photograph; not Philadelphia’s council vote, a Pennsylvania polling place or the November 2026 election. Photo: Edmond Dantès / Pexels.

Continue Reading

Trending

Join The Cannabis Aficionado Community!
Join the Cannabis Aficionado community and receive all of the most relevant news geared towards our sophisticated enthusiast community.
Loading

Copyright ©️ 2026 Cannabis Aficionado. Cannabis Aficionado is a registered trademark of CNM Inc. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service, Privacy Policy and Cookies Policy. People may receive compensation for some links to products and services. Offers may be subject to change without notice.